In this regard, results from murine tumor models showed that combining simlukafusp alfa with atezolizumab (a humanized IgG1) mAb against PDL1 (14)] improves the therapeutic effect of atezolizumab, which has been attributed to the enhanced activation of antigen-specific tumor T cells (7). Here, CD274 is linked to neoplasm.